Neuralink Receives FDA Approval to Implant Second Patient with Brain Chip

Neuralink, the Elon Musk-led company focused on developing brain-computer interfaces, has taken a major step forward in its mission with the approval to implant its experimental brain chip, named Telepathy, into a second patient. The announcement comes after the company made adjustments to its technology following the initial implantation in its first patient, who experienced complications with the device.

The Telepathy chip is designed to allow individuals to interact with computers using their thoughts, with potential applications in treating physical disabilities and neurological conditions. The company aims to expand its trials to include 10 participants this year.

The FDA's approval was granted after Neuralink proposed implanting the chip's threads deeper into the brain, addressing the movement of the brain within the skull that was observed in the initial procedure. The second patient is expected to undergo the implantation procedure in June.

Olivia Cook of Natural News reported on the story, highlighting the potential impact of the technology and the company's ongoing efforts to develop and refine its brain-computer interface.

This news is exciting for those who follow the field of neurotechnology and the potential benefits it can bring to various medical conditions and for enhancing human capabilities. It is worth noting that the development of such invasive technologies requires rigorous testing and ethical considerations to ensure the safety and well-being of participants and patients.

As Neuralink's work progresses, it will be interesting to see the outcomes of the expanded trials and the implications they may have for the future of healthcare and assistive technologies.

Read more

Prospective observational study of peripheral intravenous cannula utilisation and frequency of intravenous fluid delivery in the emergency department: convenience or necessity?

Introduction Over one billion peripheral intravenous cannulas (PIVCs) are inserted worldwide each year. Insertion of PIVCs is associated with pain, phlebitis, occlusion, and medication extravasation as well as the risk of catheter-associated infection, with an associated cost to departmental resources. Previous studies have not assessed if intravenous (IV) fluid delivery